Clinical trials: Post-COVID Condition
Myocarditis, Pericarditis
A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
The main goal of this study is to describe the clinical course, outcomes and risk factors for myocarditis and pericarditis associated with Moderna vaccination targeting SARS-CoV-2.
- Trial name
- NCT06113692
- Testing
- mRNA-1273
- Where
- 5 sites in Denmark, Norway and 2 more
- Volunteers
- 1,169 people
- Sponsor
- ModernaTX, Inc.
Psychological Stress, Psychosocial Impairment
Evaluation of the Psychosocial Impact on Health Professionals Exposed During COVID 19 Coronavirus Pandemic
Application of a survey in electronic support to hospital professionals. This survey will include different demographics as well as questions from own elaboration about the different aspects related to the development of work…
- Conditions
- Psychological Stress, Psychosocial Impairment, Anxiety, Depression
- Trial name
- NCT04752839
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
SARS-CoV-2 Infection
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.
- Trial name
- NCT05687877
- Where
- 18 sites in Japan
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
COVID-19, Long COVID
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and…
- Conditions
- COVID-19, Long COVID, Long Covid19, SARS CoV 2 Infection
- Trial name
- NCT05780450
- Testing
- Transcranial Direct Current Therapy (tDCS)
- Where
- 2 sites in Spain
- Volunteers
- 87 people
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
SARS CoV-2, Developmental Disorder
Neurological Development In Toddlers After Maternal SARS-CoV-2 Infection During Pregnancy
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a virus that causes neurological symptoms in a significant proportion of patients in addition to respiratory symptoms.
- Conditions
- SARS CoV-2, Developmental Disorder, Pregnancy Related
- Trial name
- CRONOS-Kids (NCT06968897)
- Where
- Germany
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Philipps University Marburg
Covid19, MIS-C Associated With COVID-19
Pediatric COVID Outcomes Study (PECOS)
This is a multisite prospective observational study to evaluate the clinical sequelae of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population, including…
- Conditions
- Covid19, MIS-C Associated With COVID-19, MIS-C Multisystem Inflammatory Syndrome in Children, SARS-CoV2 Infection
- Trial name
- NCT04830852
- Where
- 2 sites in United States
- Volunteers
- 1,097 people, healthy volunteers welcome
- Sponsor
- Children's National Research Institute
COVID-19
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
- Trial name
- NCT05787418
- Testing
- HH-120 Nasal Spray
- Where
- 2 sites in China
- Volunteers
- 918 people
- Sponsor
- Huahui Health
Prevention of Infectious Disease Caused by SARS-CoV-2
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA
This survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the Scientific Research Group of the Ministry of Health, Labour and Welfare at the initial stage of administration…
- Trial name
- NCT05135455
- Where
- 6 sites in Japan
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
SARS-CoV-2
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety-related information in South-Korean population.
- Trial name
- NCT06333704
- Testing
- SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5, SPIKEVAX XBB.1.5
- Where
- 26 sites in South Korea
- Volunteers
- 4,207 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection
Cardiovascular Assessment 5 Years After MIS-C
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system.
- Trial name
- NCT07659847
- Where
- Poland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Long COVID
Research of the Long-COVID-19 Syndrome in the Children
During the pandemic of the new coronavirus infection COVID-19 in the world community, in the Russian Federation, in particular in the Samara region throughout the pandemic period from the end of 2019, when the first outbreak of a…
- Trial name
- NCT05817006
- Testing
- Device
- Where
- Russia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Samara State Medical University
SARS-CoV-2
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
- Trial name
- NCT06130345
- Testing
- SPIKEVAX
- Where
- United States
- Volunteers
- 15,196,685 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C)
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
The primary objectives of this study are: To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
- Trial name
- PRISM (NCT04588363)
- Testing
- SARS-CoV-2 and/or MIS-C Exposure
- Where
- 20 sites in United States
- Volunteers
- 244 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Long COVID, Long Covid19
Stellate Ganglion Block to Treat Long COVID 19 Case Series
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.
- Conditions
- Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome
- Trial name
- NCT05812209
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Metamorphosis LTD
Myopericarditis, Myocarditis
Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old
Myopericarditis is a rare complication to messenger ribonucleic acid (mRNA) COVID-19 vaccines, especially in male adolescents and young adults. The risk in children 5-11 years old is unknown.
- Conditions
- Myopericarditis, Myocarditis, Vaccination; Complications, COVID-19 Pandemic
- Trial name
- NCT05186571
- Testing
- Pfizer-BioNTech mRNA COVID-19 vaccination
- Where
- Denmark
- Volunteers
- 350,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Covid19
CISCO-21 Prevent and Treat Long COVID-19.
Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, research studies of treatments for COVID-19 have focused on the life-threatening acute illness; few studies look at…
- Trial name
- CISCO-21 (NCT04900961)
- Testing
- Resistance Exercise
- Where
- 2 sites in United Kingdom
- Volunteers
- 233 people
- Sponsor
- NHS Greater Glasgow and Clyde
COVID-19
Evaluation of the Integration of Ag-RDTs for COVID-19 in MNCH, HIV and TB Services in Cameroon and Kenya
In many national Coronavirus Disease 2019 (COVID-19) response plans, including in Kenya and Cameroon, antigen detection tests are being used to improve access for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)…
- Trial name
- NCT05498727
- Testing
- Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics
- Where
- 2 sites in Cameroon, Kenya
- Volunteers
- 527,184 people
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
SARS-CoV-2, COVID-19
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID…
- Conditions
- SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- NCT05876377
- Testing
- Pfizer-BioNTech COVID-19 mRNA vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer